RU2003136730A - Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата - Google Patents
Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата Download PDFInfo
- Publication number
- RU2003136730A RU2003136730A RU2003136730/15A RU2003136730A RU2003136730A RU 2003136730 A RU2003136730 A RU 2003136730A RU 2003136730/15 A RU2003136730/15 A RU 2003136730/15A RU 2003136730 A RU2003136730 A RU 2003136730A RU 2003136730 A RU2003136730 A RU 2003136730A
- Authority
- RU
- Russia
- Prior art keywords
- combination according
- antibody
- insulin
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract 7
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract 7
- 150000002596 lactones Chemical class 0.000 claims abstract 7
- 150000003839 salts Chemical group 0.000 claims abstract 6
- 102000004877 Insulin Human genes 0.000 claims abstract 5
- 108090001061 Insulin Proteins 0.000 claims abstract 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims abstract 5
- 210000004027 cell Anatomy 0.000 claims abstract 5
- 150000001875 compounds Chemical class 0.000 claims abstract 5
- 229940125396 insulin Drugs 0.000 claims abstract 5
- 229940124073 Complement inhibitor Drugs 0.000 claims abstract 4
- 239000004074 complement inhibitor Substances 0.000 claims abstract 4
- 210000004698 lymphocyte Anatomy 0.000 claims abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical group C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical group C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical group CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29706901P | 2001-06-08 | 2001-06-08 | |
| US60/297,069 | 2001-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003136730A true RU2003136730A (ru) | 2005-05-20 |
Family
ID=23144725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003136730/15A RU2003136730A (ru) | 2001-06-08 | 2002-06-07 | Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20030003099A1 (enExample) |
| EP (1) | EP1429845B1 (enExample) |
| JP (1) | JP4476623B2 (enExample) |
| CN (1) | CN1524002A (enExample) |
| AT (1) | ATE424893T1 (enExample) |
| AU (1) | AU2002320828B2 (enExample) |
| BR (1) | BR0209319A (enExample) |
| CA (1) | CA2445605A1 (enExample) |
| DE (1) | DE60231522D1 (enExample) |
| ES (1) | ES2322442T3 (enExample) |
| IL (1) | IL158384A0 (enExample) |
| NO (1) | NO20035434D0 (enExample) |
| NZ (1) | NZ529044A (enExample) |
| PL (1) | PL364359A1 (enExample) |
| PT (1) | PT1429845E (enExample) |
| RU (1) | RU2003136730A (enExample) |
| WO (1) | WO2002100148A2 (enExample) |
| ZA (1) | ZA200307893B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2433117C2 (ru) * | 2005-12-15 | 2011-11-10 | Мицубиси Танабе Фарма Корпорейшн | Аминное соединение и его применение в медицинских целях |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2435739A1 (en) * | 2001-02-22 | 2002-09-06 | Novartis Ag | Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function |
| NZ551308A (en) * | 2004-05-14 | 2009-06-26 | Alexion Pharma Inc | Prolongation of survival of an allograft by inhibiting complement activity |
| ATE502630T1 (de) * | 2004-07-16 | 2011-04-15 | Kyorin Seiyaku Kk | Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen |
| SG187468A1 (en) * | 2004-11-29 | 2013-02-28 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
| JP2008530024A (ja) * | 2005-02-08 | 2008-08-07 | ノバルティス アクチエンゲゼルシャフト | Ｓ１ｐ受容体アゴニスト／モジュレーターおよび免疫抑制剤の組み合わせ剤による、抗リンパ球抗体誘導 |
| US20090191218A1 (en) * | 2005-05-11 | 2009-07-30 | Fengchun Li | DNA Vaccines And Methods For The Prevention Of Transplantation Rejection |
| ES2348701T3 (es) * | 2005-05-11 | 2010-12-10 | Loma Linda University | Composiciones y mã‰todos para prevenir y tratar trastornos inflamatorios de mediaciã“n inmune. |
| AU2007224250B2 (en) * | 2006-03-02 | 2012-05-03 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| EP2868743B1 (en) * | 2006-09-28 | 2017-11-15 | Loma Linda University | Apoptotic cell-mediated transfection of mammalian cells with interfering RNA |
| TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
| ES2653199T3 (es) * | 2008-03-12 | 2018-02-06 | Loma Linda University | Vacunas de ADN y procedimientos de prevención de rechazo tras un trasplante |
| WO2009115954A1 (en) | 2008-03-17 | 2009-09-24 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
| EP2356090B1 (en) * | 2008-11-11 | 2017-07-05 | Novartis AG | Crystalline forms of fingolimod hcl |
| JP2012508215A (ja) * | 2008-11-11 | 2012-04-05 | ノバルティス アーゲー | 有機化合物 |
| CA2957078C (en) * | 2009-06-30 | 2019-04-30 | Lifescan, Inc | Analyte testing methods and device for calculating basal insulin therapy |
| CN102483776A (zh) * | 2009-06-30 | 2012-05-30 | 生命扫描苏格兰有限公司 | 用于糖尿病管理的系统和方法 |
| IN2012DN02710A (enExample) * | 2009-09-29 | 2015-09-11 | Lifescan Scotland Ltd | |
| EP2590098B1 (en) * | 2010-02-25 | 2014-11-05 | Lifescan Scotland Limited | Analyte testing method and system with high and low blood glucose trends notification |
| US10813987B2 (en) | 2011-09-23 | 2020-10-27 | Loma Linda University | Method for inducing a tolerogenic immune response |
| US11680273B2 (en) | 2011-09-23 | 2023-06-20 | Loma Linda University | Treatment of autoimmune diseases |
| CN114306643A (zh) * | 2021-11-30 | 2022-04-12 | 中国科学院昆明动物研究所 | 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0627406B1 (en) * | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| ES2204944T3 (es) * | 1994-03-03 | 2004-05-01 | Alexion Pharmaceuticals, Inc. | Genes y proteinas de fusion inhibidores del complemento terminal. |
| GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| CA2435739A1 (en) * | 2001-02-22 | 2002-09-06 | Novartis Ag | Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function |
-
2002
- 2002-06-07 NZ NZ529044A patent/NZ529044A/en unknown
- 2002-06-07 CN CNA028098498A patent/CN1524002A/zh active Pending
- 2002-06-07 AT AT02754637T patent/ATE424893T1/de active
- 2002-06-07 CA CA002445605A patent/CA2445605A1/en not_active Abandoned
- 2002-06-07 US US10/164,755 patent/US20030003099A1/en not_active Abandoned
- 2002-06-07 ES ES02754637T patent/ES2322442T3/es not_active Expired - Lifetime
- 2002-06-07 BR BR0209319-7A patent/BR0209319A/pt not_active IP Right Cessation
- 2002-06-07 PL PL02364359A patent/PL364359A1/xx not_active Application Discontinuation
- 2002-06-07 WO PCT/EP2002/006278 patent/WO2002100148A2/en not_active Ceased
- 2002-06-07 EP EP02754637A patent/EP1429845B1/en not_active Expired - Lifetime
- 2002-06-07 PT PT02754637T patent/PT1429845E/pt unknown
- 2002-06-07 RU RU2003136730/15A patent/RU2003136730A/ru not_active Application Discontinuation
- 2002-06-07 JP JP2003502981A patent/JP4476623B2/ja not_active Expired - Fee Related
- 2002-06-07 AU AU2002320828A patent/AU2002320828B2/en not_active Ceased
- 2002-06-07 DE DE60231522T patent/DE60231522D1/de not_active Expired - Lifetime
- 2002-06-07 IL IL15838402A patent/IL158384A0/xx unknown
-
2003
- 2003-10-09 ZA ZA200307893A patent/ZA200307893B/en unknown
- 2003-12-05 NO NO20035434A patent/NO20035434D0/no not_active Application Discontinuation
-
2006
- 2006-03-09 US US11/372,383 patent/US20060153842A1/en not_active Abandoned
-
2008
- 2008-04-22 US US12/107,726 patent/US20080199465A1/en not_active Abandoned
-
2011
- 2011-06-06 US US13/154,106 patent/US20110236382A1/en not_active Abandoned
-
2013
- 2013-12-05 US US14/098,179 patent/US20140093502A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2433117C2 (ru) * | 2005-12-15 | 2011-11-10 | Мицубиси Танабе Фарма Корпорейшн | Аминное соединение и его применение в медицинских целях |
| US8809304B2 (en) | 2005-12-15 | 2014-08-19 | Mitsubishi Tanabe Pharma Corporation | Amine compound and use thereof for medical purposes |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2322442T3 (es) | 2009-06-22 |
| US20110236382A1 (en) | 2011-09-29 |
| NZ529044A (en) | 2008-03-28 |
| JP2004534788A (ja) | 2004-11-18 |
| JP4476623B2 (ja) | 2010-06-09 |
| ATE424893T1 (de) | 2009-03-15 |
| PT1429845E (pt) | 2009-06-15 |
| BR0209319A (pt) | 2004-07-20 |
| EP1429845A2 (en) | 2004-06-23 |
| US20030003099A1 (en) | 2003-01-02 |
| ZA200307893B (en) | 2004-09-06 |
| NO20035434D0 (no) | 2003-12-05 |
| WO2002100148A2 (en) | 2002-12-19 |
| IL158384A0 (en) | 2004-05-12 |
| AU2002320828B2 (en) | 2006-02-02 |
| CA2445605A1 (en) | 2002-12-19 |
| US20060153842A1 (en) | 2006-07-13 |
| PL364359A1 (en) | 2004-12-13 |
| CN1524002A (zh) | 2004-08-25 |
| US20080199465A1 (en) | 2008-08-21 |
| DE60231522D1 (de) | 2009-04-23 |
| WO2002100148A3 (en) | 2004-04-22 |
| EP1429845B1 (en) | 2009-03-11 |
| US20140093502A1 (en) | 2014-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008119842A (ru) | Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1 | |
| RU2370495C2 (ru) | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора | |
| MA58498B1 (fr) | Agonistes hétérocycliques de glp-1 | |
| RU2411239C2 (ru) | Органические соединения | |
| JP2004534788A5 (enExample) | ||
| RU2009143333A (ru) | Производные аминодигидротиазина, замещенные циклической группой | |
| DOP2005000076A (es) | "compuestos de aril-o heteroarilamida ortosustituidos" | |
| RU2010115886A (ru) | Cd19-связывающие средства и их применение | |
| MY127082A (en) | Synergistic methods and compositions for treating cancer | |
| RU2009149210A (ru) | Ингибиторы днк-зависимой протеинкиназы (днк-пк) | |
| RU2011106374A (ru) | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 | |
| JP2009532453A5 (enExample) | ||
| BR0210209A (pt) | Composições contendo zinco para uso antiviral | |
| ECSP066405A (es) | Compuestos de aril o heteroaril amida | |
| RU2003111462A (ru) | Замещенные гуанидиды коричной кислоты, способ их получения, их применение в качестве лекарственного средства, а также содержащее их лекарственное средство | |
| SV2008002969A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| KR950010890A (ko) | 폐경기 증후군의 치료방법 | |
| MX2020012827A (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes. | |
| RU2012110380A (ru) | Новое производное 5-фторурацила | |
| AR020016A2 (es) | Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento | |
| RU2011112684A (ru) | АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α | |
| RU2006146215A (ru) | Производные аминопропанола | |
| RU2003134629A (ru) | Соединения цефема | |
| RU2009114731A (ru) | Производное пиразолопиримидина | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20100413 |